AnalystsSteve BrozakSteve Brozak's Stock Forecasts
AnalystsSteve Brozak
Sectors:
Analyst Ranking
Bottom 11%
#4380 out of 4870 analysts
Average Return
-46.31%
Win Rate
11%1 out of 9
Risk vs Reward
Poor
Good
Steve Brozak's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Marker Therapeutics IncMRKR | +4.39% | $1.14 | $1.19 | 2025-03-31 - 2025-05-01 | Strong Buy |
Steve Brozak Analyst Color
Get additional color on Steve Brozak's coverage of popular stocks
Steve Brozak's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Marker Therapeutics IncMRKR | 1 | Strong Buy | $12.50 | +950.42% | Reiterates | a month ago |
Contrafect CorpCFRXQ | 2 | Strong Buy | $560.00 | N/A | Upgrades | 3 years ago |
Paratek Pharmaceuticals IncPRTK | 1 | Strong Buy | $11.00 | N/A | Upgrades | 3 years ago |
Cidara Therapeutics IncCDTX | 1 | Strong Buy | N/A | N/A | Upgrades | 4 years ago |
Omeros CorpOMER | 1 | Strong Buy | $100.00 | N/A | Maintains | 4 years ago |
Redhill Biopharma LtdRDHL | 2 | Buy | $16,000.00 | N/A | Downgrades | 4 years ago |
Cohbar IncCWBR | 1 | Buy | $135.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.